Percutaneous treatment of abdominal aortic aneurysm and aortic valve stenosis with 'staged' EVAR and TAVR: a case series

J Cardiothorac Surg. 2023 Jul 13;18(1):231. doi: 10.1186/s13019-023-02338-7.

Abstract

Symptomatic aortic valve stenosis (AS) and abdominal aortic aneurysm (AAA) are critical clinical conditions, increasingly more prevalent with aging of the population. Calcific aortic stenosis is the most common structural cardiac disease in the elderly population, and medical management of severe aortic stenosis of the elderly population is associated with poor outcomes as compared to surgical treatment. Transcatheter aortic valve replacement (TAVR) is a treatment of choice in inoperable, often elderly, patients with symptomatic severe AS and in intermediate-to-high surgical risk patients. It is not yet clarified the incidence of AAA and its impact on procedural and clinical outcomes among patients undergoing TAVR. It is known that after AS resolution with aortic valve replacement or TAVR there is an increase in blood pressure that increases the risk of dissection or abdominal aortic aneurysm rupture if AAA repair is delayed. The purpose of this report is to describe the anatomical details and technical and procedural considerations when proposing totally endovascular strategies dedicated to the treatment of patients with AS and AAA.

Keywords: Abdominal aortic aneurysm; Aortic valve stenosis; EVAR; TAVR; Transcatheter aortic valve replacement.

MeSH terms

  • Aged
  • Aortic Aneurysm, Abdominal* / complications
  • Aortic Aneurysm, Abdominal* / surgery
  • Aortic Valve / surgery
  • Aortic Valve Stenosis* / complications
  • Humans
  • Risk Factors
  • Transcatheter Aortic Valve Replacement*
  • Treatment Outcome